Well, I believe that we have a process. There's a list of substances there and we know what's of concern. We have a process to examine, at industry's cost, new substances that come into commerce.
The question of alternatives comes up very fully every time a risk management is done for a substance that's considered toxic. You're looking at what the alternatives to that are, at how far you can push this to remove it from commerce today, and at the most effective means to do that. Again, depending on where that is in the hierarchy, when you get to persistent bioaccumulative substances—